These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

708 related articles for article (PubMed ID: 18071163)

  • 1. Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials.
    Dumaine R; Borentain M; Bertel O; Bode C; Gallo R; White HD; Collet JP; Steinhubl SR; Montalescot G
    Arch Intern Med; 2007 Dec; 167(22):2423-30. PubMed ID: 18071163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-molecular-weight heparin vs. unfractionated heparin in percutaneous coronary intervention: a combined analysis.
    Borentain M; Montalescot G; Bouzamondo A; Choussat R; Hulot JS; Lechat P
    Catheter Cardiovasc Interv; 2005 Jun; 65(2):212-21. PubMed ID: 15900551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials.
    Eikelboom JW; Quinlan DJ; Mehta SR; Turpie AG; Menown IB; Yusuf S
    Circulation; 2005 Dec; 112(25):3855-67. PubMed ID: 16344381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of low molecular weight heparin with unfractionated heparin during percutaneous coronary interventions: a meta-analysis.
    Kodumuri V; Adigopula S; Singh P; Swaminathan P; Arora R; Khosla S
    Am J Ther; 2011 May; 18(3):180-9. PubMed ID: 20027109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
    Brieger D; Van de Werf F; Avezum A; Montalescot G; Kennelly BM; Granger CB; Goodman SG; Dabbous OH; Agnelli G;
    Am Heart J; 2007 Jun; 153(6):960-9. PubMed ID: 17540196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
    Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
    Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A meta-analysis of controlled clinical trials comparing low-molecular weight heparins with unfractionated heparin in unstable angina.
    Malhotra S; Karan RS; Bhargava VK; Pandhi P; Grover A; Sharma YP; Kumar R
    Indian Heart J; 2001; 53(2):197-202. PubMed ID: 11428477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-molecular-weight heparin versus unfractionated heparin in acute ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with drug-eluting stents.
    Li YJ; Rha SW; Chen KY; Poddar KL; Jin Z; Minami Y; Wang L; Dang Q; Li GP; Ramasamy S; Park JY; Choi CU; Kim JW; Kim EJ; Park CG; Seo HS; Oh DJ; Jeong MH; Ahn YK; Hong TJ; Park JS; Kim YJ; Hur SH; Seong IW; Chae JK; Cho MC; Bae JH; Choi DH; Jang YS; Chae IH; Kim HS; Kim CJ; Yoon JH; Ahn TH; Tahk SJ; Chung WS; Seung KB; Park SJ;
    Am Heart J; 2010 Apr; 159(4):684-690.e1. PubMed ID: 20362730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
    Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ
    Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial.
    Mehta SR; Steg PG; Granger CB; Bassand JP; Faxon DP; Weitz JI; Afzal R; Rush B; Peters RJ; Natarajan MK; Velianou JL; Goodhart DM; Labinaz M; Tanguay JF; Fox KA; Yusuf S;
    Circulation; 2005 Mar; 111(11):1390-7. PubMed ID: 15781750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison of unfractionated heparin and low molecular weight heparin in pulmonary thromboembolism: meta-analysis].
    Zhai ZG; Wang C; Liu YM; Qin ZQ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Jun; 26(3):221-6. PubMed ID: 15266820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial.
    White HD; Gallo R; Cohen M; Steg PG; Aylward PE; Bode C; Steinhubl S; Montalescot G
    Am Heart J; 2009 Jan; 157(1):125-31. PubMed ID: 19081408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis. A meta-analysis of the randomized trials.
    De Luca G; Marino P
    Am Heart J; 2007 Dec; 154(6):1085.e1-6. PubMed ID: 18035079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2 evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial.
    Rao SV; Melloni C; Myles-Dimauro S; Broderick S; Kosinski AS; Kleiman NS; Dzavík V; Tanguay JF; Chandna H; Gammon R; Rivera E; Alexander JH; Fier I; Roach J; Becker RC;
    Circulation; 2010 Apr; 121(15):1713-21. PubMed ID: 20368520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial.
    Sabatine MS; Morrow DA; Montalescot G; Dellborg M; Leiva-Pons JL; Keltai M; Murphy SA; McCabe CH; Gibson CM; Cannon CP; Antman EM; Braunwald E;
    Circulation; 2005 Dec; 112(25):3846-54. PubMed ID: 16291601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials.
    Mismetti P; Laporte-Simitsidis S; Tardy B; Cucherat M; Buchmüller A; Juillard-Delsart D; Decousus H
    Thromb Haemost; 2000 Jan; 83(1):14-9. PubMed ID: 10669147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.
    Chen JL; Chen J; Qiao SB; Guo YL; Wu YJ; Dai J; Yuan JQ; Qin XW; Yang YJ; Gao RL
    Chin Med J (Engl); 2006 Mar; 119(5):355-9. PubMed ID: 16542576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.
    Mehta SR; Granger CB; Eikelboom JW; Bassand JP; Wallentin L; Faxon DP; Peters RJ; Budaj A; Afzal R; Chrolavicius S; Fox KA; Yusuf S
    J Am Coll Cardiol; 2007 Oct; 50(18):1742-51. PubMed ID: 17964037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
    White HD; Kleiman NS; Mahaffey KW; Lokhnygina Y; Pieper KS; Chiswell K; Cohen M; Harrington RA; Chew DP; Petersen JL; Berdan LG; Aylward PE; Nessel CC; Ferguson JJ; Califf RM
    Am Heart J; 2006 Dec; 152(6):1042-50. PubMed ID: 17161049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?
    Kamphuisen PW; Agnelli G
    Thromb Res; 2007; 119(3):265-74. PubMed ID: 16674999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.